NCT07008547

To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 202 (actual)
• Sponsor: SPH-BIOCAD (HK) Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with moderate to severe plaque psoriasis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	Netakimab	Netakimab administered subcutaneously
DRUG	Placebo	Placebo administered subcutaneously

Timeline

• Start date: 2024-07-30
• Primary completion: 2025-03-28
• Completion: 2025-06-13
• First posted: 2025-06-06
• Last updated: 2026-04-15

Locations

1 site across 1 country: China